Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting

This was a retrospective observational study to examine treatment patterns, molecular testing patterns, treatment response, and clinical outcomes among patients initiating first-line (1L) tyrosine kinase inhibitor (TKI) treatment for CML-CP in The United States (US) Oncology Network practices. Patients who initiated 1L therapy between 01 January 2016 and 31 December 2022 were eligible for inclusion in the study. Study-eligible patients were followed longitudinally post-index until death (if the patient had documentation of death during the study observation period) or last available patient record that occurred on or before the end of the study observation period. The study observation period was from 01 January 2016 to 30 November 2023. The index date was defined as the start date of 1L therapy for CML-CP.

NCT Number	NCT07374120
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Leukemia, Myeloid, Chronic-Phase
Enrollment	1,480 participants
Start Date	2024-02-01
Primary Completion	2025-01-21 (estimated)
Study Completion	2025-01-21 (estimated)
Updated on ClinicalTrials.gov	2026-02-02